Compass Pathways PLC (MEX:CMPSN)

Q1 2025 Compass Pathways PLC Earnings Call Transcript

May 8, 2025 / 12:00 PM GMT

Release Date Price: MXN92.98

Transcript 8-K10-Q

Key Points

Positve

Compass Pathways PLC (CMPS) completed dosing in Part A of their pivotal phase 3 trial for treatment-resistant depression (TRD), marking a significant milestone.
The company anticipates sharing 6-week top-line results in late June, which could demonstrate a meaningful improvement in treatment durability.
A recent study published in the Journal of Clinical Psychology showed long-term benefits of a single 25 mg dose of CO 360 psilocybin, with an average time to depressive event of over 12 weeks.
Compass Pathways PLC (CMPS) has a strong financial position with $260 million in cash and cash equivalents, expected to fund operations through the second phase 3 trial results in 2026.
The company has established strategic collaborations, including with Healthport, to ensure broad and equitable access to their treatments if approved.

Negative

The phase 2 follow-up study data was not as comprehensive as desired, leading to some limitations in interpreting the results.
There is ongoing concern about suicidality as a potential side effect, which remains a topic of scrutiny and discussion.
The company faces challenges in predicting placebo effects in their trials, which can complicate efficacy assessments.
Manufacturing plans for the US are still in development, with no specific timeline for the additional site.
There is uncertainty regarding the regulatory landscape and potential tariffs that could impact manufacturing and commercialization.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CMPS.OQ - Compass Pathways PLC
Q1 2025 Compass Pathways PLC Earnings Call
May 08, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by and welcome to the Compas Pathways first quarter 2025 earnings call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session. If you'd like to ask a question during that time, please press star followed by one on your telephone keypad.

Thank you. I'd now like to hand the call over to Steve Schulz, senior Vice President of investor relations. You may now begin, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Welcome all of you and thank you for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.